Drug Overview
Simdax (levosimendan; Orion/Tenax Therapeutics) is a calcium-sensitizing agent indicated for the treatment of acute decompensated heart failure (ADHF) in situations where conventional therapy is not sufficient. It acts by binding to cardiac troponin C in a calcium-dependent manner. Its pharmacological effects include increased cardiac contractility mediated by calcium sensitization of troponin C, vasodilation based on the opening of potassium channels in the vasculature, and cardioprotection due to the opening of mitochondrial potassium channels in the cardiomyocytes.
Simdax (levosimendan; Orion/Tenax Therapeutics) is a calcium-sensitizing agent indicated for the treatment of acute decompensated heart failure (ADHF) in situations where conventional therapy is not sufficient. It acts by binding to cardiac troponin C in a calcium-dependent manner. Its pharmacological effects include increased cardiac contractility mediated by calcium sensitization of troponin C, vasodilation based on the opening of potassium channels in the vasculature, and cardioprotection due to the opening of mitochondrial potassium channels in the cardiomyocytes.
Table of Contents
1 Product Profiles
List of Figures
List of Tables
Companies Mentioned
- Orion
- Tenax Therapeutics
